Not listed NON-INVASIVE STAGING OF METASTASIS BY PRECISION MRI - PROJECT SUMMARY/ABSTRACT THIS SBIR APPLICATION WILL DEVELOP AN IMPROVED CONTRAST AGENT FOR PRECISION STAGING THROUGH EARLY AND ACCURATE DETECTION OF PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) LIVER METASTASIS. WE HAVE CREATED AN INNOVATIVE PLATFORM TECHNOLOGY USING A NEW CLASS OF PROTEIN-BASED MRI CONTRAST AGENTS (PROCAS) FOR CONTRAST-ENHANCED MRI. WE HAVE DEVELOPED AN EFFECTIVE APPROACH TO GENERATE PROTEIN CONTRAST AGENTS AGAINST AN ARRAY OF MOLECULAR BIOMARKERS INCLUDING COLLAGEN I (PROCA32.COLLAGEN). THIS EXTRACELLULAR MATRIX PROTEIN IS HIGHLY EXPRESSED IN THE TUMOR MICROENVIRONMENT AND ITS EXPRESSION LEVELS AND CROSSLINKING INCREASE UPON PROGRESSION. PROCA32.COLLAGEN EXHIBITS 10- TO 50-FOLD INCREASE IN BOTH R1 AND R2 RELAXIVITIES, COMPARED TO CLINICALLY-APPROVED GD3+ CONTRAST AGENTS, RESULTING IN EXCEPTIONAL IMAGING CAPABILITY THAT CAN DISCERN HETEROGENEOUS TISSUE SIGNALS VIA A DUAL MR IMAGING METHODOLOGY. PROCA32.COLLAGEN HAS STRONG COLLAGEN BINDING AFFINITY, ENABLES EARLY DETECTION OF SMALL LIVER METASTASES $0 1/8/26 Not listed NON-INVASIVE STAGING OF METASTASIS BY PRECISION MRI - PROJECT SUMMARY/ABSTRACT THIS SBIR APPLICATION WILL DEVELOP AN IMPROVED CONTRAST AGENT FOR PRECISION STAGING THROUGH EARLY AND ACCURATE DETECTION OF PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) LIVER METASTASIS. WE HAVE CREATED AN INNOVATIVE PLATFORM TECHNOLOGY USING A NEW CLASS OF PROTEIN-BASED MRI CONTRAST AGENTS (PROCAS) FOR CONTRAST-ENHANCED MRI. WE HAVE DEVELOPED AN EFFECTIVE APPROACH TO GENERATE PROTEIN CONTRAST AGENTS AGAINST AN ARRAY OF MOLECULAR BIOMARKERS INCLUDING COLLAGEN I (PROCA32.COLLAGEN). THIS EXTRACELLULAR MATRIX PROTEIN IS HIGHLY EXPRESSED IN THE TUMOR MICROENVIRONMENT AND ITS EXPRESSION LEVELS AND CROSSLINKING INCREASE UPON PROGRESSION. PROCA32.COLLAGEN EXHIBITS 10- TO 50-FOLD INCREASE IN BOTH R1 AND R2 RELAXIVITIES, COMPARED TO CLINICALLY-APPROVED GD3+ CONTRAST AGENTS, RESULTING IN EXCEPTIONAL IMAGING CAPABILITY THAT CAN DISCERN HETEROGENEOUS TISSUE SIGNALS VIA A DUAL MR IMAGING METHODOLOGY. PROCA32.COLLAGEN HAS STRONG COLLAGEN BINDING AFFINITY, ENABLES EARLY DETECTION OF SMALL LIVER METASTASES $0 4/4/25 Not listed NON-INVASIVE STAGING OF METASTASIS BY PRECISION MRI - PROJECT SUMMARY/ABSTRACT THIS SBIR APPLICATION WILL DEVELOP AN IMPROVED CONTRAST AGENT FOR PRECISION STAGING THROUGH EARLY AND ACCURATE DETECTION OF PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) LIVER METASTASIS. WE HAVE CREATED AN INNOVATIVE PLATFORM TECHNOLOGY USING A NEW CLASS OF PROTEIN-BASED MRI CONTRAST AGENTS (PROCAS) FOR CONTRAST-ENHANCED MRI. WE HAVE DEVELOPED AN EFFECTIVE APPROACH TO GENERATE PROTEIN CONTRAST AGENTS AGAINST AN ARRAY OF MOLECULAR BIOMARKERS INCLUDING COLLAGEN I (PROCA32.COLLAGEN). THIS EXTRACELLULAR MATRIX PROTEIN IS HIGHLY EXPRESSED IN THE TUMOR MICROENVIRONMENT AND ITS EXPRESSION LEVELS AND CROSSLINKING INCREASE UPON PROGRESSION. PROCA32.COLLAGEN EXHIBITS 10- TO 50-FOLD INCREASE IN BOTH R1 AND R2 RELAXIVITIES, COMPARED TO CLINICALLY-APPROVED GD3+ CONTRAST AGENTS, RESULTING IN EXCEPTIONAL IMAGING CAPABILITY THAT CAN DISCERN HETEROGENEOUS TISSUE SIGNALS VIA A DUAL MR IMAGING METHODOLOGY. PROCA32.COLLAGEN HAS STRONG COLLAGEN BINDING AFFINITY, ENABLES EARLY DETECTION OF SMALL LIVER METASTASES $0 9/19/23 Not listed NON-INVASIVE STAGING OF METASTASIS BY PRECISION MRI - PROJECT SUMMARY/ABSTRACT THIS SBIR APPLICATION WILL DEVELOP AN IMPROVED CONTRAST AGENT FOR PRECISION STAGING THROUGH EARLY AND ACCURATE DETECTION OF PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) LIVER METASTASIS. WE HAVE CREATED AN INNOVATIVE PLATFORM TECHNOLOGY USING A NEW CLASS OF PROTEIN-BASED MRI CONTRAST AGENTS (PROCAS) FOR CONTRAST-ENHANCED MRI. WE HAVE DEVELOPED AN EFFECTIVE APPROACH TO GENERATE PROTEIN CONTRAST AGENTS AGAINST AN ARRAY OF MOLECULAR BIOMARKERS INCLUDING COLLAGEN I (PROCA32.COLLAGEN). THIS EXTRACELLULAR MATRIX PROTEIN IS HIGHLY EXPRESSED IN THE TUMOR MICROENVIRONMENT AND ITS EXPRESSION LEVELS AND CROSSLINKING INCREASE UPON PROGRESSION. PROCA32.COLLAGEN EXHIBITS 10- TO 50-FOLD INCREASE IN BOTH R1 AND R2 RELAXIVITIES, COMPARED TO CLINICALLY-APPROVED GD3+ CONTRAST AGENTS, RESULTING IN EXCEPTIONAL IMAGING CAPABILITY THAT CAN DISCERN HETEROGENEOUS TISSUE SIGNALS VIA A DUAL MR IMAGING METHODOLOGY. PROCA32.COLLAGEN HAS STRONG COLLAGEN BINDING AFFINITY, ENABLES EARLY DETECTION OF SMALL LIVER METASTASES $1.0m 8/30/23 Not listed NON-INVASIVE STAGING OF METASTASIS BY PRECISION MRI - PROJECT SUMMARY/ABSTRACT THIS SBIR APPLICATION WILL DEVELOP AN IMPROVED CONTRAST AGENT FOR PRECISION STAGING THROUGH EARLY AND ACCURATE DETECTION OF PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) LIVER METASTASIS. WE HAVE CREATED AN INNOVATIVE PLATFORM TECHNOLOGY USING A NEW CLASS OF PROTEIN-BASED MRI CONTRAST AGENTS (PROCAS) FOR CONTRAST-ENHANCED MRI. WE HAVE DEVELOPED AN EFFECTIVE APPROACH TO GENERATE PROTEIN CONTRAST AGENTS AGAINST AN ARRAY OF MOLECULAR BIOMARKERS INCLUDING COLLAGEN I (PROCA32.COLLAGEN). THIS EXTRACELLULAR MATRIX PROTEIN IS HIGHLY EXPRESSED IN THE TUMOR MICROENVIRONMENT AND ITS EXPRESSION LEVELS AND CROSSLINKING INCREASE UPON PROGRESSION. PROCA32.COLLAGEN EXHIBITS 10- TO 50-FOLD INCREASE IN BOTH R1 AND R2 RELAXIVITIES, COMPARED TO CLINICALLY-APPROVED GD3+ CONTRAST AGENTS, RESULTING IN EXCEPTIONAL IMAGING CAPABILITY THAT CAN DISCERN HETEROGENEOUS TISSUE SIGNALS VIA A DUAL MR IMAGING METHODOLOGY. PROCA32.COLLAGEN HAS STRONG COLLAGEN BINDING AFFINITY, ENABLES EARLY DETECTION OF SMALL LIVER METASTASES $1.0m 8/30/23